Caris Life Sciences Q2 2025 revenue $181.4M (+81% YoY); Adj. EBITDA positive $16.7M; FY rev guidance $675-685M

Caris Life Sciences, Inc.

2025-Q2 EPS reported -$12.80 revenue$302,314,000

Total revenue $181.4M, up 81.3% YoY; gross margin 62.7% vs 37.5% a year ago.
Net loss $71.8M includes $37.1M one-time IPO conversion expense; positive Adj. EBITDA $16.7M and positive free cash flow $5.9M.
Clinical therapy selection volume 50,032 cases (+22% YoY); MI Profile volume +17.7%, Caris Assure volume +56.3%.
FY2025 revenue guidance $675-685M (64-66% growth); clinical volume growth expected 19-21%.
Recent IPO raised $519.5M net; cash and securities $724.9M at June 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.